HB Surface Antigen Level as a Useful Predictor for the Treatment Response to Tenofovir Alafenamide in Nucleoside Analogue Naïve Chronic Hepatitis B.

Matsui, Masahiro; Asai, Akira; Ushiro, Kosuke; Yokohama, Keisuke; Fukunishi, Shinya; Kim, Soo Ki; Nishikawa, Hiroki

Matsui, Masahiro; Asai, Akira; Ushiro, Kosuke; Yokohama, Keisuke; Fukunishi, Shinya; Kim, Soo Ki; Nishikawa, Hiroki.

Afiliação

Matsui M; The Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Asai A; The Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Ushiro K; The Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Yokohama K; The Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Fukunishi S; The Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Kim SK; The Premier Departmental Research of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Nishikawa H; Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan.

In Vivo ; 37(2): 726-733, 2023.

Article em En | MEDLINE | ID: mdl-36881081

Assuntos

Antígenos de Superfície; Hepatite B Crônica; Humanos; Antígenos de Superfície da Hepatite B; Nucleosídeos; DNA Viral; Hepatite B Crônica/tratamento farmacológico

Palavras-chave

Chronic hepatitis B; HBsAg; Tenofovir alafenamide; predictor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite B Crônica / Antígenos de Superfície Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: In Vivo Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google